Breast cancer１ | Discussion・Q&A

解説【LBA18】Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP)for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): additional analyses ofDESTINY-Breast09 in key subgroups of interest

齋藤 亜由美
（国立がん研究センター中央病院）

解説【LBA1】Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with highriskhuman epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) withresidual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05

齋藤 亜由美
（国立がん研究センター中央病院）

解説【291O】DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel+ trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)

齋藤 亜由美
（国立がん研究センター中央病院）